Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spruce Biosciences Inc (NQ: SPRB )

0.5194 +0.0361 (+7.47%)
Streaming Delayed Price Updated: 2:54 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Spruce Biosciences Inc

< Previous 1 2 3 4 5 6 7 Next >
Why Is Spruce Biosciences (SPRB) Stock Down 78% Today?
Spruce Biosciences stock is falling hard on Thursday as investors in SPRB shares react to the latest clinical trial data reported. 
Via InvestorPlace
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Robinhood Markets, Inc. (NASDAQ: HOOD) rose sharply in today’s pre-market trading after the company reported February trading metrics. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of all the biggest pre-market stock movers worth watching on Thursday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
What 4 Analyst Ratings Have To Say About Spruce Biosciences
Via Benzinga
Spruce Biosciences Inc. (NASDAQ: SPRB) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
From Spruce Biosciences, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic on Tuesday and we're diving into all of the biggest winners and losers this morning! 
Via InvestorPlace
Analyst Ratings for Spruce Biosciences
Via Benzinga
Expert Ratings for Spruce Biosciences
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Jefferies London Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Top 4 Health Care Stocks That May Rocket Higher This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia
From Spruce Biosciences, Inc.
Via Business Wire
Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Why Smith & Wesson Brands Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers Impel Pharmaceuticals Inc. (NASDAQ: IMPL) rose 41.3% to $0.54 in pre-market trading after falling 4% on Thursday. 
Via Benzinga
Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean... 
Via Benzinga
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Spruce Biosciences
Via Business Wire
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Jefferies Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.